Report

Effect of p53 Status on Tumor Response to Antiangiogenic Therapy

See allHide authors and affiliations

Science  22 Feb 2002:
Vol. 295, Issue 5559, pp. 1526-1528
DOI: 10.1126/science.1068327

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Abstract

The p53 tumor suppressor gene is inactivated in the majority of human cancers. Tumor cells deficient in p53 display a diminished rate of apoptosis under hypoxic conditions, a circumstance that might reduce their reliance on vascular supply, and hence their responsiveness to antiangiogenic therapy. Here, we report that mice bearing tumors derived from p53 −/− HCT116 human colorectal cancer cells were less responsive to antiangiogenic combination therapy than mice bearing isogenicp53 +/+ tumors. Thus, although antiangiogenic therapy targets genetically stable endothelial cells in the tumor vasculature, genetic alterations that decrease the vascular dependence of tumor cells can influence the therapeutic response of tumors to this therapy.

  • * To whom correspondence should be addressed. E-mail: robert.kerbel{at}swchsc.on.ca

View Full Text